NCT05849922

A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa

A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study Assessing the Efficacy and Safety of an Anti-TNF-OX40L NANOBODY® Molecule, SAR442970, in Participants With Moderate to Severe Hidradenitis Suppurativa

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 86 (actual)
• Sponsor: Sanofi · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This was a Phase 2 study in adult participants with moderate to severe hidradenitis suppurativa (HS). The purpose of the study was to evaluate the efficacy and safety of SAR442970 compared to placebo.

Detailed description

The study duration was up to 40 weeks.

Conditions

• Hidradenitis Suppurativa

Interventions

Type	Name	Description
DRUG	SAR442970	1 mL extractable volume of 150 mg/mL SAR442970 filled in 2 mL glass vial
DRUG	Placebo	1 mL extractable volume of placebo filled in 2 mL glass vial

Timeline

• Start date: 2023-06-06
• Primary completion: 2024-08-22
• Completion: 2025-01-09
• First posted: 2023-05-09
• Last updated: 2026-01-29
• Results posted: 2026-01-29

Locations

45 sites across 15 countries: United States, Australia, Belgium, Canada, Chile, Czechia, Denmark, France, Germany, Greece, Italy, Netherlands, Poland, Spain, Sweden

Regulatory

• FDA-regulated drug study